ABL Bio announced that it will receive a USD 40 million upfront payment for the licence, research and collaboration agreement for its Grabody platform, and a USD 15 million equity investment from Eli Lilly and Company.

ABL Bio and Lilly are currently conducting joint research and development on multiple therapeutic candidates leveraging the Grabody platform across various modalities.

In parallel with strengthening its collaboration with Lilly, ABL Bio plans to accelerate R&D on its core technologies—including the bispecific antibody platform 'Grabody,' bispecific ADCs and dual-payload ADCs—using the newly secured funding.

Speaking in this regard, Sang Hoon Lee, CEO, ABL Bio, said, "With the completion of the relevant administrative procedures, including the HSR Act, ABL Bio will receive the upfront payment and equity investment from Lilly. The company plans to use the newly secured funding to expand the indications of its Grabody platform into high-unmet-need areas such as obesity and muscle disorders. ABL Bio also intends to extend clinical development of its bispecific immuno-oncology candidates into combination therapies and focus on advancing next-generation ADC programmes."

Meanwhile, on 12 and 14 November 2025, ABL Bio signed a licence, research and collaboration agreement for Grabody platform with Lilly valued at USD 2.602 billion (including a USD 40 million upfront payment), as well as a USD 15 million equity investment agreement. Based on these agreements, ABL Bio explores a broad range of collaborative opportunities with Lilly to develop therapies from a long-term perspective.